M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

INTRODUCTION 19
Hereditary frontotemporal dementia (FTD) is a neurodegenerative disorder, predominantly expansion in the C9orf72 gene (Renton, et al., 2011 ,Seelaar, et al., 2011 . Increasing 23 evidence confirms the presence of pathophysiological and subsequent neuroanatomical 24 changes in the presymptomatic stage of genetic FTD and amyotrophic lateral sclerosis (ALS) 25 (Bertrand, et al., 2017 ,Borroni, et al., 2008 ,Caroppo, et al., 2015 ,Cash, et al., 2017 ,Dopper, 26 et al., 2014 ,Floeter, et al., 2016 ,Jiskoot, et al., 2016 ,Jiskoot, et al., 2018 ,Lee, et al., 27 2017 ,Meeter, et al., 2016 ,Meeter, 2018 ,Meeter, et al., 2017 ,Papma, et al., 2017 ,Pievani, et 28 al., 2014 ,Rohrer, et al., 2015 ,Rohrer, et al., 2013 ,Walhout, et al., 2015 ,Whitwell, et al., 29 2011a . Previous MRI studies have revealed gene-specific neuroimaging profiles in healthy 30 carriers of pathogenic FTD mutations (hereafter referred as 'presymptomatic mutation 31 carriers') (Bertrand, et al., 2017 ,Borroni, et al., 2008 ,Caroppo, et al., 2015 ,Cash, et al., 32 2017 ,Dopper, et al., 2014 ,Lee, et al., 2017 ,Papma, et al., 2017 ,Pievani, et al., 2014 ,Rohrer, 33 et al., 2015 ,Walhout, et al., 2015 . In presymptomatic MAPT mutation carriers, lower gray 34 matter (GM) volume in the anterior temporal lobes has been found (Cash, et al., (Rohrer, et al., 2015) . WM loss in presymptomatic C9orf72 repeat expansion carriers M A N U S C R I P T
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process starts several years before clinical symptom onset, studies that examine longitudinal 50 presymptomatic GM and WM changes in specific mutations are scarce (Rohrer, et al., 51 2015 ,Schuster, et al., 2015 . Understanding longitudinal presymptomatic FTD related brain 52 changes is important, as it enables both the identification of vulnerable brain regions as well 53 as the timeframe and progression of brain changes, with important implications for disease 54 management and treatment (Schuster, et al., 2015) . Progression of gray and white matter 55 changes in presymptomatic FTD carriers may follow a gradual trajectory, similar to the 56 presymptomatic stage of other neurodegenerative diseases like Alzheimer's disease (AD),
57
shown in the Dominant Inherited Alzheimer Network (DIAN) study (Bateman, et al., 58 2012 ,Benzinger, et al., 2013 ,Kinnunen, et al., 2018 ,Rohrer, et al., 2015 , but could also 59 deviate from findings in AD. For example, remarkable early brain changes have been found 60 in C9orf72 repeat expansion carriers which may indicate that C9orf72 repeat expansion 61 associated pathology knows an early start and progresses in a very slow manner (Papma, et 62 al., 2017 ,Rohrer, et al., 2015 , or could even exist as a neurodevelopmental disorder (Lee, et 63 al., 2017 ,Walhout, et al., 2015 . On the other hand, previous research demonstrated that 
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mentioned above with surface based cortical thickness estimation for baseline and follow-up 160 images, using projection-based thickness (Dahnke, et al., 2013 
174
Diffusion weighted images were preprocessed using TBSS as described previously (Dopper, 175 et al., 2014 ,Papma, et al., 2017 . We used the FMRIB58_FA derived skeleton instead of a study-specific skeleton to allow for comparisons across baseline, follow-up and longitudinal analyses. Skeletonized FA and mean diffusivity (MD) images were fed into voxel-wise group 178 statistics for cross-sectional baseline and follow-up analyses, to investigate the effect of 179 mutation group. For the longitudinal analysis, follow-up FA and MD images were subtracted 180 from their corresponding baseline maps, to determine the amount of change in white matter 181 integrity over time for each participant, and compared between groups with an ANOVA.
182
Comparisons were performed using permutation-based testing (5,000 permutations), with 
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with non-carriers at baseline, follow-up or in longitudinal analyses. In addition, non-carriers
271
did not show any loss of GM volume or cortical thinning compared to GRN mutation carriers.
272
Furthermore, we did not find significant differences in FA or MD between GRN mutation 273 carriers and non-carriers. (Bertrand, et al., 2017 ,Rohrer, et al., 2015 ,Walhout, et al., 337 2015 . This has been explained previously as either following a trajectory with an early onset 338 and very slow progression of atrophy (Rohrer, et al., 2015) , or as a neurodevelopmental 339 disorder (Lee, et al., 2017 ,Walhout, et al., 2015 . Though our results agree with early GM 340 and WM differences in presymptomatic C9orf72 repeat expansion carriers compared with 341 non-carriers, we cannot comment on the underlying mechanism. Stable lower GM volume 342 may indicate a neurodevelopmental process, but could also mean that our two year follow up
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period is not sufficient to detect very slow progressive brain changes.
Our findings of extensive subcortical WM differences at baseline between C9orf72
repeat expansion carriers and non-carriers are in line with previous studies, indicating early M A N U S C R I P T A C C E P T E D Seeley, 2010 ,Zhou, et al., 2010 .
355
The GM and WM regions that were affected in our cross-sectional analyses in
356
C9orf72 repeat expansion carriers were in accordance with expected pathology in FTD and
357
ALS (Floeter, et al., 2016) , e.g. orbitofrontal, temporal and insula atrophy are associated with 358 behavioural variant FTD (Gordon, et al., 2016 ,Meeter, et al., 2017 ,Seelaar, et al., 2011 -Knock, et al., 2015 ,Floeter, et al., 2016 ,Liu, et al., 2014 . In line with this reasoning, 
377
At follow up, we found cortical GM thinning in the right temporal lobe in 378 presymptomatic MAPT mutation carriers, and GM volume loss in the left temporal pole and 379 parahippocampal gyrus, which is line with previous cross-sectional presymptomatic MAPT 380 studies (Rohrer et al., 2015 , Dopper et al., 2014 , Cash et al., 2017 , and resembles the 381 atrophy pattern found in symptomatic MAPT carriers (Gordon, et al., 2016 ,Rohrer, et al., 382 2010 ,Whitwell, et al., 2015 ,Whitwell, et al., 2012 (Hutton, et al., 2009 , Gerrits, et al., 2016 . VBM relies on 392 a mixture of measurements in cortical thickness, cortical surface areas and folding of the gyri 393 (Ashburner et al., 2000) . When used together, voxel-based cortical thickness analysis could 394 aid understanding of underlying GM differences, especially in age-related brain changes 395 (Hutton, et al., 2009 , Pereira, et al., 2012 , 2016) , and ranges till before 40 in some families (Seelaar, et al., 2011) . Therefore, the majority of our MAPT mutation carriers are likely within one or two decades before symptom M A N U S C R I P T
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onset. The present findings combined with previous functional MRI, cognitive and GM 401 studies (Jiskoot, et al., 2016 ,Rohrer, et al., 2015 ,Whitwell, et al., 2011a indicate that GM and
402
WM loss in presymptomatic MAPT carriers gradually progressed in a period of five to ten 403 years before symptom onset, starting in the temporal lobe, followed by slowly progressive 404 cognitive decline.
405
The absence of any significant changes in a relatively large cohort of presymptomatic
406
GRN mutation carriers compared to non-carriers in the present study is a remarkable finding,
407
supported by previous cross-sectional studies (Cash, et al., 2017 ,Dopper, et al., 2014 example in the GENFI study (Rohrer, et al., 2015) . However, using estimated years to onset in longitudinal mixed effects models may be disadvantageous, as large intra-familiar 450 heterogeneity in age at disease onset has been reported in genetic FTD mutations 451 (Olszewska, et al., 2016 , Seelaar, et al., 2011 , van Mossevelde, et al., 2017 . Our follow-up
452
and longitudinal results may have been slightly compromised by a software upgrade on our M A N U S C R I P T
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In conclusion, this study shows distinct presymptomatic GM 
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HIGHLIGHTS
Presymptomatic brain changes differ across FTD mutations compared to non-carriers
In presymptomatic C9orf72 carriers, cross-sectional brain change is stable over time
In presymptomatic MAPT carriers, longitudinal changes occur in the temporal lobes
